Literature DB >> 9041381

Effect of colchiceine and ursodeoxycholic acid on hepatocyte and erythrocyte membranes and liver histology in experimentally induced carbon tetrachloride cirrhosis in rats.

A A Nava-Ocampo1, S Suster, P Muriel.   

Abstract

Colchiceine and ursodeoxycholic acid (UDCA) are drugs currently in use as therapy for different types of liver damage. We evaluated their ability to reverse the damage induced by carbon tetrachloride (CCl4) in rats. Six groups were analysed: (1) CCl4 (0.4 g kg(-1), i.p., three times a week) for 13 weeks; (2) CCl4 for 8 weeks followed by colchiceine (60 microg kg(-1)) + CCl4 for 5 weeks; (3) CCl4 for 8 weeks and thereafter UDCA (25 mg kg(-1)) + CCl4 for 5 weeks. Groups 4, 5 and 6 were appropriate controls of colchiceine, UDCA and vehicles respectively. Na+,K+- and Ca2+-ATPase activities and the cholesterol-phospholipid (CH/PL) ratio from erythrocyte and hepatocyte membranes were quantified. Membrane enzymatic activities and CH/PL ratios were affected more in group 1 than groups 2 and 3. We concluded that colchiceine and UDCA were effective drugs in this model of liver damage.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9041381     DOI: 10.1046/j.1365-2362.1997.910615.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  6 in total

Review 1.  Current and future anti-fibrotic therapies for chronic liver disease.

Authors:  Don C Rockey
Journal:  Clin Liver Dis       Date:  2008-11       Impact factor: 6.126

Review 2.  Use of mesenchymal stem cells to treat liver fibrosis: current situation and future prospects.

Authors:  Silvia Berardis; Prenali Dwisthi Sattwika; Mustapha Najimi; Etienne Marc Sokal
Journal:  World J Gastroenterol       Date:  2015-01-21       Impact factor: 5.742

3.  Current status of novel antifibrotic therapies in patients with chronic liver disease.

Authors:  Michal Cohen-Naftaly; Scott L Friedman
Journal:  Therap Adv Gastroenterol       Date:  2011-11       Impact factor: 4.409

Review 4.  Hepatoprotective and Anti-fibrotic Agents: It's Time to Take the Next Step.

Authors:  Ralf Weiskirchen
Journal:  Front Pharmacol       Date:  2016-01-07       Impact factor: 5.810

Review 5.  Translating an understanding of the pathogenesis of hepatic fibrosis to novel therapies.

Authors:  Don C Rockey
Journal:  Clin Gastroenterol Hepatol       Date:  2013-01-07       Impact factor: 11.382

6.  The Effects of Taoren-Honghua Herb Pair on Pathological Microvessel and Angiogenesis-Associated Signaling Pathway in Mice Model of CCl4-Induced Chronic Liver Disease.

Authors:  Shengyan Xi; Lifeng Yue; Mengmeng Shi; Ying Peng; Yangxinzi Xu; Xinrong Wang; Qian Li; Zhijun Kang; Hanjing Li; Yanhui Wang
Journal:  Evid Based Complement Alternat Med       Date:  2016-05-11       Impact factor: 2.629

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.